Olanzapine and haloperidol in first episode psychosis

Two-year data

A. I. Green, J. A. Lieberman, R. M. Hamer, I. D. Glick, R. E. Gur, R. S. Kahn, Joseph Patrick McEvoy, D. O. Perkins, A. J. Rothschild, T. Sharma, M. F. Tohen, S. Woolson, R. B. Zipursky

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Few studies have assessed the comparative efficacy and safety of atypical and typical antipsychotic medications in patients within their first episode of psychosis. This study examined the effectiveness of the atypical antipsychotic olanzapine and the typical antipsychotic haloperidol in patients experiencing their first episode of a schizophrenia-related psychotic disorder over a 2-year treatment period. Two hundred and sixty-three patients were randomized to olanzapine or haloperidol in a doubleblind, multisite, international 2-year study. Clinical symptoms and side effects were assessed at baseline and longitudinally following randomization for the duration of the study. Olanzapine and haloperidol treatment were both associated with substantial and comparable reductions in symptom severity (the primary outcome measure) over the course of the study. However, the treatment groups differed on two secondary efficacy measures. Patients were less likely to discontinue treatment with olanzapine than with haloperidol: mean time (in days) in the study was significantly greater for those treated with olanzapine compared to haloperidol (322.09 vs. 230.38, p < 0.0085). Moreover, remission rates were greater in patients treated with olanzapine as compared to those treated with haloperidol (57.25% vs. 43.94%, p < 0.036). While extrapyramidal side effects were greater in those treated with haloperidol, weight gain, cholesterol level and liver function values were greater in patients treated with olanzapine. The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine.

Original languageEnglish (US)
Pages (from-to)234-243
Number of pages10
JournalSchizophrenia Research
Volume86
Issue number1-3
DOIs
StatePublished - Sep 1 2006

Fingerprint

olanzapine
Haloperidol
Psychotic Disorders
Antipsychotic Agents
Therapeutics
Random Allocation

Keywords

  • First episode
  • Haloperidol
  • Olanzapine
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. E., Kahn, R. S., ... Zipursky, R. B. (2006). Olanzapine and haloperidol in first episode psychosis: Two-year data. Schizophrenia Research, 86(1-3), 234-243. https://doi.org/10.1016/j.schres.2006.06.021

Olanzapine and haloperidol in first episode psychosis : Two-year data. / Green, A. I.; Lieberman, J. A.; Hamer, R. M.; Glick, I. D.; Gur, R. E.; Kahn, R. S.; McEvoy, Joseph Patrick; Perkins, D. O.; Rothschild, A. J.; Sharma, T.; Tohen, M. F.; Woolson, S.; Zipursky, R. B.

In: Schizophrenia Research, Vol. 86, No. 1-3, 01.09.2006, p. 234-243.

Research output: Contribution to journalArticle

Green, AI, Lieberman, JA, Hamer, RM, Glick, ID, Gur, RE, Kahn, RS, McEvoy, JP, Perkins, DO, Rothschild, AJ, Sharma, T, Tohen, MF, Woolson, S & Zipursky, RB 2006, 'Olanzapine and haloperidol in first episode psychosis: Two-year data', Schizophrenia Research, vol. 86, no. 1-3, pp. 234-243. https://doi.org/10.1016/j.schres.2006.06.021
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS et al. Olanzapine and haloperidol in first episode psychosis: Two-year data. Schizophrenia Research. 2006 Sep 1;86(1-3):234-243. https://doi.org/10.1016/j.schres.2006.06.021
Green, A. I. ; Lieberman, J. A. ; Hamer, R. M. ; Glick, I. D. ; Gur, R. E. ; Kahn, R. S. ; McEvoy, Joseph Patrick ; Perkins, D. O. ; Rothschild, A. J. ; Sharma, T. ; Tohen, M. F. ; Woolson, S. ; Zipursky, R. B. / Olanzapine and haloperidol in first episode psychosis : Two-year data. In: Schizophrenia Research. 2006 ; Vol. 86, No. 1-3. pp. 234-243.
@article{b322956d9f494c568785a3c51bd35e2d,
title = "Olanzapine and haloperidol in first episode psychosis: Two-year data",
abstract = "Few studies have assessed the comparative efficacy and safety of atypical and typical antipsychotic medications in patients within their first episode of psychosis. This study examined the effectiveness of the atypical antipsychotic olanzapine and the typical antipsychotic haloperidol in patients experiencing their first episode of a schizophrenia-related psychotic disorder over a 2-year treatment period. Two hundred and sixty-three patients were randomized to olanzapine or haloperidol in a doubleblind, multisite, international 2-year study. Clinical symptoms and side effects were assessed at baseline and longitudinally following randomization for the duration of the study. Olanzapine and haloperidol treatment were both associated with substantial and comparable reductions in symptom severity (the primary outcome measure) over the course of the study. However, the treatment groups differed on two secondary efficacy measures. Patients were less likely to discontinue treatment with olanzapine than with haloperidol: mean time (in days) in the study was significantly greater for those treated with olanzapine compared to haloperidol (322.09 vs. 230.38, p < 0.0085). Moreover, remission rates were greater in patients treated with olanzapine as compared to those treated with haloperidol (57.25{\%} vs. 43.94{\%}, p < 0.036). While extrapyramidal side effects were greater in those treated with haloperidol, weight gain, cholesterol level and liver function values were greater in patients treated with olanzapine. The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine.",
keywords = "First episode, Haloperidol, Olanzapine, Psychosis, Schizophrenia",
author = "Green, {A. I.} and Lieberman, {J. A.} and Hamer, {R. M.} and Glick, {I. D.} and Gur, {R. E.} and Kahn, {R. S.} and McEvoy, {Joseph Patrick} and Perkins, {D. O.} and Rothschild, {A. J.} and T. Sharma and Tohen, {M. F.} and S. Woolson and Zipursky, {R. B.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.schres.2006.06.021",
language = "English (US)",
volume = "86",
pages = "234--243",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Olanzapine and haloperidol in first episode psychosis

T2 - Two-year data

AU - Green, A. I.

AU - Lieberman, J. A.

AU - Hamer, R. M.

AU - Glick, I. D.

AU - Gur, R. E.

AU - Kahn, R. S.

AU - McEvoy, Joseph Patrick

AU - Perkins, D. O.

AU - Rothschild, A. J.

AU - Sharma, T.

AU - Tohen, M. F.

AU - Woolson, S.

AU - Zipursky, R. B.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Few studies have assessed the comparative efficacy and safety of atypical and typical antipsychotic medications in patients within their first episode of psychosis. This study examined the effectiveness of the atypical antipsychotic olanzapine and the typical antipsychotic haloperidol in patients experiencing their first episode of a schizophrenia-related psychotic disorder over a 2-year treatment period. Two hundred and sixty-three patients were randomized to olanzapine or haloperidol in a doubleblind, multisite, international 2-year study. Clinical symptoms and side effects were assessed at baseline and longitudinally following randomization for the duration of the study. Olanzapine and haloperidol treatment were both associated with substantial and comparable reductions in symptom severity (the primary outcome measure) over the course of the study. However, the treatment groups differed on two secondary efficacy measures. Patients were less likely to discontinue treatment with olanzapine than with haloperidol: mean time (in days) in the study was significantly greater for those treated with olanzapine compared to haloperidol (322.09 vs. 230.38, p < 0.0085). Moreover, remission rates were greater in patients treated with olanzapine as compared to those treated with haloperidol (57.25% vs. 43.94%, p < 0.036). While extrapyramidal side effects were greater in those treated with haloperidol, weight gain, cholesterol level and liver function values were greater in patients treated with olanzapine. The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine.

AB - Few studies have assessed the comparative efficacy and safety of atypical and typical antipsychotic medications in patients within their first episode of psychosis. This study examined the effectiveness of the atypical antipsychotic olanzapine and the typical antipsychotic haloperidol in patients experiencing their first episode of a schizophrenia-related psychotic disorder over a 2-year treatment period. Two hundred and sixty-three patients were randomized to olanzapine or haloperidol in a doubleblind, multisite, international 2-year study. Clinical symptoms and side effects were assessed at baseline and longitudinally following randomization for the duration of the study. Olanzapine and haloperidol treatment were both associated with substantial and comparable reductions in symptom severity (the primary outcome measure) over the course of the study. However, the treatment groups differed on two secondary efficacy measures. Patients were less likely to discontinue treatment with olanzapine than with haloperidol: mean time (in days) in the study was significantly greater for those treated with olanzapine compared to haloperidol (322.09 vs. 230.38, p < 0.0085). Moreover, remission rates were greater in patients treated with olanzapine as compared to those treated with haloperidol (57.25% vs. 43.94%, p < 0.036). While extrapyramidal side effects were greater in those treated with haloperidol, weight gain, cholesterol level and liver function values were greater in patients treated with olanzapine. The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine.

KW - First episode

KW - Haloperidol

KW - Olanzapine

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=33747398701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747398701&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2006.06.021

DO - 10.1016/j.schres.2006.06.021

M3 - Article

VL - 86

SP - 234

EP - 243

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -